Plantibodies, a biotech company focused on developing a sustainable platform for oral biologics, has successfully secured $585,000 in new funding. This investment round marks a significant milestone for the company as it advances its innovative approach to drug production and delivery, attracting capital from investors keen on supporting its mission. The capital infusion will support Plantibodies' ongoing efforts to bring its groundbreaking technology to market, aiming to enhance patient care through more accessible and effective treatments.
The company's core technology leverages molecular farming and synthetic biology to produce humanized monoclonal antibodies within edible plant leaves. This method offers a distinct advantage over traditional animal cell-based production, significantly reducing the carbon footprint and slashing production costs by over 90%. Furthermore, Plantibodies' approach yields medications with remarkable room temperature stability, addressing critical challenges in drug storage and distribution.
By enabling effortless storage and potential worldwide distribution, Plantibodies aims to facilitate at-home treatment for a range of diseases, including cancers, inflammations, metabolic diseases, and infections. This innovative delivery mechanism seeks to eliminate the need for burdensome intravenous injections typically administered in hospital settings, thereby positively impacting lives globally. The recently secured funding is crucial for accelerating the development and scaling of this transformative platform, enabling the company to move closer to its commercialization goals.
Plantibodies plans to deploy the newly raised capital to accelerate its research and development initiatives, scale its production platform, and strategically expand its team. This strategic investment positions Plantibodies to continue its trajectory in transforming biologic drug production and delivery, aiming for broader accessibility and improved patient outcomes globally.
